



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

ACBI2

Cat. No.:	HY-151623
CAS No.:	2913161-19-8
Molecular Formula:	C ₅₆ H ₆₈ BrFN ₈ O ₅ S
Molecular Weight:	1064.16
Target:	PROTACs; Epigenetic Reader Domain
Pathway:	PROTAC; Epigenetics
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (117.46 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		0.9397 mL	4.6985 mL	9.3971 mL
	5 mM		0.1879 mL	0.9397 mL	1.8794 mL
	10 mM		0.0940 mL	0.4699 mL	0.9397 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	ACBI2 is a highly potent and orally active VHL PROTAC SMARCA2 degrader (EC ₅₀ : 7 nM), which selectively degrades SMARCA2 with a DC ₅₀ value of 1 nM in RKO cells. ACBI2 can be used in the research of lung cancer ^[1] .	
IC ₅₀ & Target	VHL 7 nM (EC ₅₀)	SMARCA2
In Vitro	ACBI2 degrades SMARCA2 and SMARCA4 in RKO cells, with DC ₅₀ s of 1 nM and 32 nM respectively ^[1] . ACBI2 (0.1 nM-1 μM, 4-18 h) rapidly and completely degrades SMARCA2 in two sensitive cell lines (A549 and NCI-H1568) ^[1] . ACBI2 (1 nM-1 μM, 18 h) significantly degrades SMARCA2 with clear selectivity over SMARCA4 ^[1] . ACBI2 (0-1 μM; 18 h) dose-dependently degrades SMARCA2 in human whole blood ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	ACBI2 (80 mg/kg, p.o., once daily) significantly inhibits tumor growth in an A549 xenograft mice model ^[1] . ACBI2 (5-100 mg/kg, p.o., tumors collected 24 or 48 h after treatment) dose-dependently degrades tumor SMARCA2 in A549 engrafted tumor bearing mice (IHC staining) ^[1] . ACBI2 (30 mg/kg, p.o., mice) shows oral bioavailability of 22% ^[1] .	

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	A549 xenograft mice model ^[1]
Dosage:	80 mg/kg
Administration:	Oral administration (p.o.), once daily
Result:	Inhibited tumor growth and was well tolerated.

CUSTOMER VALIDATION

- Cell Chem Biol. 2024 Oct 1:S2451-9456(24)00396-9.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Kofink C, et al. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nat Commun. 2022 Oct 10;13(1):5969.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA